General MedicationsORALGeneric
NEVIRAPINE
NEVIRAPINE
Standard Dose
400MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview NEVIRAPINE is listed in Drugs@FDA under application 207698 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient NEVIRAPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 400MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-11-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview NEVIRAPINE is listed in Drugs@FDA under application 207698 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NEVIRAPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 400MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-11-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.